Novavax Inc NVAX.O announced on Friday that it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates the development of vaccines to protect against subvariants BA.4 and BA.5.
The U.S. FDA on Thursday recommended that manufacturers of COVID-19 vaccines change the design of their booster vaccines starting this fall to include components tailored to combat Omicron’s currently dominant BA.4 and BA.5 subvariants are.
How reliable are Omicron rapid antigen tests?
Novavax expects additional preclinical data on vaccines tailored to the rapidly spreading subvariants of Omicron in late summer or fall.
US doctors are looking after the end of Roe v. Wade an increase in vasectomies: report
Massive cruise ship brawl captured on video calls for Coast Guard intervention
The company’s vaccine, which is based on an earlier strain of the virus, has not yet been approved in the United States and is currently under review by the US Food and Drug Administration.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
https://globalnews.ca/news/8961786/novavax-covid-vaccine-omicron/ Novavax Expects to Make Omicron COVID-19 Vaccine by Fall – National